{"id":"https://openalex.org/W3112374784","doi":"https://doi.org/10.1002/alz.041198","title":"Effects of azeliragon on ADAS\u2010cog and CDR domains and individual items in patients with mild Alzheimer's disease and type 2 diabetes (T2D)","display_name":"Effects of azeliragon on ADAS\u2010cog and CDR domains and individual items in patients with mild Alzheimer's disease and type 2 diabetes (T2D)","publication_year":2020,"publication_date":"2020-12-01","ids":{"openalex":"https://openalex.org/W3112374784","doi":"https://doi.org/10.1002/alz.041198","mag":"3112374784"},"language":"en","primary_location":{"id":"doi:10.1002/alz.041198","doi":"https://doi.org/10.1002/alz.041198","is_oa":false,"landing_page_url":"https://doi.org/10.1002/alz.041198","pdf_url":null,"source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's & Dementia","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060983204","display_name":"Aaron H. Burstein","orcid":"https://orcid.org/0009-0008-0176-9184","observed_orcids":["https://orcid.org/0009-0008-0176-9184"]},"institutions":[{"id":"https://openalex.org/I4210155842","display_name":"vTv Therapeutics (United States)","ror":"https://ror.org/051vfhx38","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155842"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Aaron H. Burstein","raw_affiliation_strings":["vTv Therapeutics LLC  High Point NC USA","vTv Therapeutics LLC, High Point, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"vTv Therapeutics LLC  High Point NC USA","institution_ids":["https://openalex.org/I4210155842"]},{"raw_affiliation_string":"vTv Therapeutics LLC, High Point, NC, USA","institution_ids":["https://openalex.org/I4210155842"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019816635","display_name":"Imogene McCanless Dunn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155842","display_name":"vTv Therapeutics (United States)","ror":"https://ror.org/051vfhx38","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155842"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Imogene Dunn","raw_affiliation_strings":["vTv Therapeutics LLC  High Point NC USA","vTv Therapeutics LLC, High Point, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"vTv Therapeutics LLC  High Point NC USA","institution_ids":["https://openalex.org/I4210155842"]},{"raw_affiliation_string":"vTv Therapeutics LLC, High Point, NC, USA","institution_ids":["https://openalex.org/I4210155842"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ann M. Gooch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155842","display_name":"vTv Therapeutics (United States)","ror":"https://ror.org/051vfhx38","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155842"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann M. Gooch","raw_affiliation_strings":["vTv Therapeutics LLC  High Point NC USA","vTv Therapeutics LLC, High Point, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"vTv Therapeutics LLC  High Point NC USA","institution_ids":["https://openalex.org/I4210155842"]},{"raw_affiliation_string":"vTv Therapeutics LLC, High Point, NC, USA","institution_ids":["https://openalex.org/I4210155842"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004137322","display_name":"Carmen Valcarce","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155842","display_name":"vTv Therapeutics (United States)","ror":"https://ror.org/051vfhx38","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155842"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carmen Valcarce","raw_affiliation_strings":["vTv Therapeutics LLC  High Point NC USA","vTv Therapeutics LLC, High Point, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"vTv Therapeutics LLC  High Point NC USA","institution_ids":["https://openalex.org/I4210155842"]},{"raw_affiliation_string":"vTv Therapeutics LLC, High Point, NC, USA","institution_ids":["https://openalex.org/I4210155842"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5060983204"],"corresponding_institution_ids":["https://openalex.org/I4210155842"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":null,"fwci":0.3203,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.60934458,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"16","issue":"S9","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.8916000127792358,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.8916000127792358,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.09719999879598618,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11142","display_name":"Advanced Glycation End Products research","score":0.008100000210106373,"subfield":{"id":"https://openalex.org/subfields/1308","display_name":"Clinical Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9309999942779541}],"concepts":[{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6801811456680298},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6603567600250244},{"id":"https://openalex.org/C2779484449","wikidata":"https://www.wikidata.org/wiki/Q412189","display_name":"Memantine","level":4,"score":0.6400603652000427},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6260936260223389},{"id":"https://openalex.org/C2780904820","wikidata":"https://www.wikidata.org/wiki/Q415081","display_name":"Donepezil","level":4,"score":0.6146131157875061},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.5480437874794006},{"id":"https://openalex.org/C2781172350","wikidata":"https://www.wikidata.org/wiki/Q194520","display_name":"Atrophy","level":2,"score":0.5143717527389526},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.32199275493621826},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.25771892070770264},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.14471417665481567},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1002/alz.041198","doi":"https://doi.org/10.1002/alz.041198","is_oa":false,"landing_page_url":"https://doi.org/10.1002/alz.041198","pdf_url":null,"source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's & Dementia","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/2","display_name":"Zero hunger","score":0.6200000047683716}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4243627385","https://openalex.org/W2357138848","https://openalex.org/W2894526927","https://openalex.org/W2168333595","https://openalex.org/W4390201772","https://openalex.org/W2747467504","https://openalex.org/W1982119121","https://openalex.org/W3148260052","https://openalex.org/W2765085470","https://openalex.org/W2371638215"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Azeliragon,":[2],"an":[3,17],"oral":[4],"antagonist":[5],"of":[6,132,135,226,256],"the":[7,128,160,168,266,315],"receptor":[8],"for":[9,25,183,262,293],"advanced":[10],"glycation":[11],"endproducts":[12],"(RAGE),":[13],"was":[14,80,103,273],"evaluated":[15,210],"in":[16,37,109,167,203,265,336,344],"18\u2010month":[18],"Phase":[19],"3":[20],"study":[21],"as":[22,151],"a":[23,38,104,163],"treatment":[24,99,136],"patients":[26,47,71,111,221,345],"with":[27,73,112,137,170,177,252,333,346],"mild":[28,114,347],"Alzheimer\u2019s":[29],"disease":[30],"(AD)":[31],"(the":[32],"STEADFAST":[33,102,144],"Study).":[34],"Post\u2010hoc":[35],"analyses":[36],"T2D":[39,171],"subgroup":[40],"(HbA1c":[41,172],"\u2265":[42,173],"6.5%)":[43,174],"found":[44],"that":[45,326],"azeliragon\u2010treated":[46],"exhibited":[48],"less":[49,53,57,60,263,334],"cognitive":[50,282],"decline":[51,264,335],"(ADAS\u2010cog11),":[52],"whole":[54],"brain":[55],"atrophy,":[56,59],"hippocampal":[58],"ventricular":[61],"enlargement,":[62],"and":[63,85,89,130,185,189,216,229,239,249,258,306,314,339,349],"reduced":[64],"plasma":[65],"inflammatory":[66],"cytokine":[67],"concentrations":[68],"compared":[69],"to":[70,82,93,98,142],"treated":[72],"placebo.":[74,143],"The":[75],"current":[76],"retrospective":[77],"exploratory":[78],"analysis":[79],"performed":[81],"evaluate":[83],"ADAS\u2010cog":[84,237,294],"CDR":[86,118,186,281,316],"symptom":[87,190],"domains":[88,241],"individual":[90,187],"test":[91],"items":[92,313],"ascertain":[94],"which":[95],"were":[96,175,196,209,235,242,278,291],"sensitive":[97],"effects.":[100],"Method":[101],"randomized,":[105],"double\u2010blind,":[106],"placebo\u2010controlled":[107],"trial":[108],"875":[110],"probable":[113],"AD":[115,348],"(MMSE":[116],"21\u201026,":[117],"global":[119],"0.5\u20101)":[120],"receiving":[121],"stable":[122],"acetylcholinesterase":[123],"inhibitors":[124],"and/or":[125],"memantine,":[126],"evaluating":[127],"efficacy":[129],"safety":[131],"18":[133,205,233,342],"months":[134,343],"azeliragon":[138,247,290,327],"5":[139],"mg/day":[140],"relative":[141],"included":[145],"two":[146],"separate":[147],"studies":[148],"(A\u2010Study":[149],"completed":[150],"planned,":[152],"B\u2010Study":[153],"prematurely":[154],"terminated":[155],"following":[156],"negative":[157],"results":[158],"from":[159,180,207],"A\u2010Study)":[161],"under":[162],"single":[164],"protocol.":[165],"Patients":[166],"A\u2010Study":[169],"analyzed":[176],"mean":[178],"changes":[179],"baseline":[181,208],"calculated":[182],"ADAS\u2010cog11":[184],"item":[188,318],"domain":[191,268],"scores.":[192],"Standard":[193],"effects":[194],"sizes":[195],"determined":[197],"using":[198,211],"Cohen":[199,253],"d.":[200],"Treatment":[201],"differences":[202,277,288],"Month":[204,232],"change":[206],"both":[212],"t\u2010test":[213],"(presented":[214],"herein)":[215],"Wilcoxon":[217],"test.":[218],"Result":[219],"Forty\u2010seven":[220],"(26":[222],"azeliragon,":[223],"21":[224],"placebo":[225,332],"whom":[227],"19":[228],"17":[230],"had":[231],"data)":[234],"analyzed.":[236],"Language":[238],"Praxis":[240],"nominally":[243],"significantly":[244],"different":[245],"favoring":[246,289],"(p=0.01":[248],"p=0.049,":[250],"respectively)":[251],"d":[254],"values":[255],"0.86":[257],"0.66.":[259],"A":[260],"trend":[261],"Memory":[267,317],"(p=0.07,":[269],"effect":[270,297,303,310,320],"size":[271,298,304,311,321],"0.62)":[272,312],"noted.":[274],"No":[275],"significant":[276,287],"noted":[279,292],"on":[280],"or":[283],"functional":[284],"domains.":[285],"Nominal":[286],"comprehension":[295],"(p=0.005,":[296],"0.99),":[299],"ideational":[300],"praxis":[301,340],"(p=0.012,":[302],"0.84)":[305],"spoken":[307],"language":[308],"(p=0.067,":[309],"(p=0.032,":[319],"0.73).":[322],"Conclusion":[323],"Results":[324],"suggest":[325],"may":[328],"have":[329],"benefits":[330],"over":[331,341],"memory,":[337],"language,":[338],"T2D.":[350]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2025-10-10T00:00:00"}